NCT03322800View on ClinicalTrials.gov

A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

October 23, 2017

Primary Completion Date

April 6, 2018

Study Completion Date

May 24, 2018

Conditions
Healthy
Interventions
DRUG

AK0529

Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral

OTHER

Placebo

Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral

Trial Locations (1)

201203

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Ark Biopharmaceutical Co., Ltd.

INDUSTRY

NCT03322800 - A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers | Biotech Hunter | Biotech Hunter